Related Experiment Video
Updated: Dec 6, 2025

Human Serum Anti-aquaporin-4 Immunoglobulin G Detection by Cell-based Assay
Published on: April 5, 2019
Could aquaporin modulators be employed as prospective drugs for COVID-19 related pulmonary comorbidity?
Lezy Flora Mariajoseph-Antony1, Arun Kannan1, Antojenifer Panneerselvam1
1Molecular Endocrinology Laboratory, Department of Biochemistry, Centre for Excellence in Life Sciences, Bharathidasan University, Tiruchirappalli 620 024, India.
Abstract:
COVID-19 initially an epidemic caused by SARS-CoV-2 has turned out to be a life- threatening global pandemic with increased morbidity and mortality. The presence of cytokine storm has been linked with the pathogenesis of severe lung injury as evinced in COVID-19. Aquaporins (AQPs) are molecular water channels, facilitating water transport across the cell membrane in response to osmotic gradients. Impairment in alveolar fluid clearance due to altered functional expression of respiratory AQPs highlight their pathophysiological significance in pulmonary edema associated respiratory illness. Therefore, we hypothesize that targeted modulation of AQPs in lungs in the intervening period of time, could diminish the dreadful effects of inflammation- induced comorbidity in COVID-19.
Related Concept Videos
Aquaporins
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
Open Angle Glaucoma: Treatment
Drugs such as carbonic anhydrase inhibitors, α2- and...
Heart Failure Drugs: Diuretics
COPD: Management Using Bronchodilators and Corticosteroids
Upper Respiratory Drugs: Decongestants
Most decongestants are readily available over-the-counter in...

